Literature DB >> 16698763

A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations.

A Federico, M Trappoliere, C Tuccillo, I de Sio, A Di Leva, C Del Vecchio Blanco, C Loguercio.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16698763      PMCID： PMC1856214          DOI： 10.1136/gut.2006.091967

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  8 in total

1.  Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention.

Authors:  J Zhao; R Agarwal
Journal:  Carcinogenesis       Date:  1999-11       Impact factor: 4.944

Review 2.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

Review 3.  Nonalcoholic steatohepatitis: definition and pathology.

Authors:  E M Brunt
Journal:  Semin Liver Dis       Date:  2001       Impact factor: 6.115

4.  WHO and ADA criteria for the diagnosis of diabetes mellitus in relation to body mass index. Insulin sensitivity and secretion in resulting subcategories of glucose tolerance.

Authors:  N Melchionda; G Forlani; G Marchesini; L Baraldi; S Natale
Journal:  Int J Obes Relat Metab Disord       Date:  2002-01

Review 5.  Hepatitis C: epidemiology and review of complementary/alternative medicine treatments.

Authors:  L Patrick
Journal:  Altern Med Rev       Date:  1999-08

6.  Serum markers detect the presence of liver fibrosis: a cohort study.

Authors:  William M C Rosenberg; Michael Voelker; Robert Thiel; Michael Becka; Alastair Burt; Detlef Schuppan; Stefan Hubscher; Tania Roskams; Massimo Pinzani; Michael J P Arthur
Journal:  Gastroenterology       Date:  2004-12       Impact factor: 22.682

7.  Obesity and non-alcoholic fatty liver disease in chronic hepatitis C.

Authors:  Zobair M Younossi; Arthur J McCullough; Janus P Ong; David S Barnes; Anthony Post; Anthony Tavill; Diane Bringman; Lisa M Martin; Jennifer Assmann; Terry Gramlich; Kevin D Mullen; Robert O'Shea; William D Carey; Roy Ferguson
Journal:  J Clin Gastroenterol       Date:  2004-09       Impact factor: 3.062

Review 8.  The use of alternative medicine in the treatment of hepatitis C.

Authors:  Pamela Bean
Journal:  Am Clin Lab       Date:  2002-05
  8 in total
  20 in total

Review 1.  Silybin and the liver: from basic research to clinical practice.

Authors:  Carmela Loguercio; Davide Festi
Journal:  World J Gastroenterol       Date:  2011-05-14       Impact factor: 5.742

2.  Current status of therapy in nonalcoholic Fatty liver disease.

Authors:  Scott McNear; Stephen A Harrison
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

3.  Silybin and metabolic disorders.

Authors:  Pasquale Pignatelli; Roberto Carnevale; Danilo Menichelli
Journal:  Intern Emerg Med       Date:  2018-10-17       Impact factor: 3.397

4.  Silybin counteracts lipid excess and oxidative stress in cultured steatotic hepatic cells.

Authors:  Giulia Vecchione; Elena Grasselli; Adriana Voci; Francesca Baldini; Ignazio Grattagliano; David Qh Wang; Piero Portincasa; Laura Vergani
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

Review 5.  Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection.

Authors:  Stephen J Polyak; Peter Ferenci; Jean-Michel Pawlotsky
Journal:  Hepatology       Date:  2013-03       Impact factor: 17.425

6.  Silymarin in non alcoholic fatty liver disease.

Authors:  Fulvio Cacciapuoti; Anna Scognamiglio; Rossella Palumbo; Raffaele Forte; Federico Cacciapuoti
Journal:  World J Hepatol       Date:  2013-03-27

7.  Current treatments in nonalcoholic steatohepatitis.

Authors:  Dawn M Torres; Stephen A Harrison
Journal:  Curr Treat Options Gastroenterol       Date:  2007-12

8.  The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study.

Authors:  Carmela Loguercio; Alessandro Federico; Marco Trappoliere; Concetta Tuccillo; Ilario de Sio; Agnese Di Leva; Marco Niosi; Mauro Valeriano D'Auria; Rita Capasso; Camillo Del Vecchio Blanco
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

9.  Quantitative proteomics analysis based on tandem mass tag labeling coupled with labeling coupled with liquid chromatography-tandem mass spectrometry discovers the effect of silibinin on non-alcoholic fatty liver disease in mice.

Authors:  Yichao Wang; Hang Zhao; Liying Yang; He Zhang; Xian Yu; Wenjie Fei; Yunfeng Zhen; Zhe Gao; Shuchun Chen; Luping Ren
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

10.  Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study.

Authors:  Ali Akbar Hajiaghamohammadi; Amir Ziaee; Sonia Oveisi; Homa Masroor
Journal:  Hepat Mon       Date:  2012-08-03       Impact factor: 0.660
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.